Title Category Credit Event datesort ascending Cost
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
02/25/2021 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Expert Exchange 2021: A Practical Guide to Navigating Novelty in Bladder Cancer: Equipping Clinicians in an Era of Rapid Change
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
02/11/2021 $0.00 CEC Oncology has incorporated our “Expert Exchange” format for educational activities most recently in our 2020 bladder cancer activities. This Expert Exchange-based format is an educational modality which incorporates elements of a traditional Oxford-style debate, provides enhanced audience interactivity, a broader platform for diverse clinical perspectives, and a flexible framework within which to incorporate evolving science and breaking data. Activity attendees will be immersed a lively and dynamic discussion between key thought leaders in the world of bladder cancer.
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
02/10/2021 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Betting on BTK Inhibitors in CLL: Where are We Now and Where are We Going?
  • Oncology
  • ACPE Pharmacy
  • Participation
01/26/2021 $0.00 This initiative is targeted to addressing the professional practice of pharmacists in hospitals, health systems, ambulatory care clinics, and other settings. Attendees of this activity will gain insight into the latest clinical and scientific advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL) using BTK inhibitors (BTKis), including the latest approvals, the most current safety and efficacy data, and expert insights into addressing challenges of CLL treatment using BTKis.
Betting on BTK Inhibitors in CLL: Where are We Now and Where are We Going?
  • Oncology
  • ACPE Pharmacy
  • Participation
01/13/2021 $0.00 This initiative is targeted to addressing the professional practice of pharmacists in hospitals, health systems, ambulatory care clinics, and other settings. Attendees of this activity will gain insight into the latest clinical and scientific advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL) using BTK inhibitors (BTKis), including the latest approvals, the most current safety and efficacy data, and expert insights into addressing challenges of CLL treatment using BTKis.
Betting on BTK Inhibitors in CLL: Where are We Now and Where are We Going?
  • Oncology
  • ACPE Pharmacy
  • Participation
01/12/2021 $0.00 This initiative is targeted to addressing the professional practice of pharmacists in hospitals, health systems, ambulatory care clinics, and other settings. Attendees of this activity will gain insight into the latest clinical and scientific advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL) using BTK inhibitors (BTKis), including the latest approvals, the most current safety and efficacy data, and expert insights into addressing challenges of CLL treatment using BTKis.
Stepping Beyond the Status Quo in Heart Failure: The Revolutionary Role of SGLT2 Inhibition
  • Cardiology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
01/06/2021 $0.00 This Grand Rounds initiative is targeted to cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants. Designed to foster meaningful interprofessional and interdisciplinary collaboration, this accredited activity will explore the evolution of SGLT2 inhibition in the era of cardiovascular outcomes trials (CVOTs), as well as evaluate foundational mechanisms linking type 2 diabetes (T2D) to heart failure (HF).
New Horizons in HER2+ Breast Cancer: Pharmacist-Focused Strategies and Insights
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00 Presented by Creative Educational Concepts, Inc. (CEC) and supported through independent educational grants from AstraZeneca and Daiichi Sankyo.
Navigating a Changing Landscape in TNBC: Pharmacist-Focused Strategies in the Era of Immunotherapy
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00 Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from Merck & Co., Inc.
Pharmacist Perspectives: Exploring the Evolving Role of BTK Inhibitors in CLL
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00 Participants will gain exposure to emerging clinical and scientific advances in the treatment of chronic lymphocytic leukemia (CLL) with BTK inhibitors (BTKis), including novel pharmacologic targets within the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for BTK inhibitors in both treatment-naïve (TN) and relapsed/refractory (R/R) CLL. Prominent mechanisms of BTK inhibitor resistance and adaptive strategies used to prevent and/or mitigate the development of resistance also will be explored.

Pages